查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1469134

基于电动车的液体活检市场 - 全球行业规模、份额、趋势、机会和预测，按产品、工作流程、技术、样本类型、最终用户、地区和竞争细分，2019-2029F

EV-Based Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering, By Workflow, By Technology, By Sample Type, By End user, By Region and Competition, 2019-2029F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2023 年，全球基于EV 的液体活检市场估值为8,910 万美元，预计在预测期内将出现令人印象深刻的成长，到2029 年复合年增长率为9.58%。成长，原因如下：对微创癌症诊断的偏好日益增加，以及老年人口的不断增长。此外，全球用于开发新液体活检测试的临床研究数量的增加进一步刺激了市场。基于EV（细胞外囊泡）的液体活检市场是医疗和生物技术产业中新兴且前景广阔的领域。

主要市场驱动因素

与 CfDNA 或 CTC 相比，外泌体的丰度和稳定性显着提高

癌症盛行率上升

研究开发投资不断增加

技术进步

主要市场挑战

标准化品质管制

样品稳定性和储存

主要市场趋势

新型电动汽车生物标记的出现

将应用扩展到肿瘤学之外

细分市场洞察

提供见解

工作流程见解

区域洞察

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：临床试验分析

第 5 章：客户之声

第 6 章：全球基于 EV 的液体活检市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 依产品提供（试剂盒及检测、服务、仪器）
    • 依工作流程（样品製备、定序、数据分析）
    • 按技术（隔离技术、分析技术）
    • 依样本类型（血液、尿液、唾液等）
    • 按最终用户（学术和研究机构、製药和生物技术公司、临床实验室）
    • 按地区
    • 按公司划分 (2023)
  • 市场地图

第 7 章：北美基于 EV 的液体活检市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 透过奉献
    • 按工作流程
    • 依技术
    • 依样品类型
    • 按最终用户
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 加拿大
    • 墨西哥

第 8 章：欧洲基于 EV 的液体活检展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 透过提供
    • 按工作流程
    • 依技术
    • 依样品类型
    • 按最终用户
    • 按国家/地区
  • 欧洲：国家分析
    • 德国基于电动车的液体活检市场展望
    • 义大利基于电动车的液体活检市场展望
    • 法国基于电动车的液体活检市场展望
    • 西班牙基于电动车的液体活检市场展望
    • 英国基于电动车的液体活检市场展望

第 9 章：亚太地区基于 EV 的液体活检市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 透过提供
    • 按工作流程
    • 依技术
    • 依样品类型
    • 按最终用户
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国

第 10 章：中东和非洲基于电动车的液体活检市场前景

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 透过提供
    • 按工作流程
    • 依技术
    • 依样品类型
    • 按最终用户
    • 按国家/地区
  • 中东和非洲：国家分析
    • 阿联酋
    • 沙乌地阿拉伯
    • 南非

第 11 章：南美洲基于 EV 的液体活检市场展望

  • 市场规模预测
    • 按价值
  • 市占率预测
    • 透过提供
    • 按工作流程
    • 依技术
    • 依样品类型
    • 按最终用户
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 12 章：市场动态

  • 司机
  • 挑战

第 13 章：市场趋势发展

  • 併购（如有）
  • 产品发布（如有）
  • 最近的发展

第 14 章：波特五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第15章：竞争格局

  • Horiba Ltd.
  • Thermo Fisher Scientific, Inc
  • Lonza Group AG
  • Takara Bio Inc
  • Abcam plc
  • Qiagen NV
  • Malvern Panalytical Ltd
  • Revvity, Inc. (PerkinElmer, Inc)
  • Norgen Biotek Corp
  • Bio-Techne Corporation

第 16 章：策略建议

第 17 章：关于我们免责声明

简介目录
Product Code: 15834

Global EV-Based Liquid Biopsy Market was valued at USD 89.10 Million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.58% through 2029. The market for EV based liquid biopsy is witnessing growth due to factors such as increasing preference for minimally invasive cancer diagnostics, and the growing geriatric population. In addition, the market is further stimulated by an increase in the global number of clinical studies for the development of new liquid biopsy tests. The EV (extracellular vesicle) based liquid biopsy market is an emerging and promising field in the medical and biotechnology industries.

Key Market Drivers

Abundance Remarkable Stability of Exosomes Compared to CfDNA or CTCs

The abundance and remarkable stability of exosomes compared to circulating cell-free DNA (cfDNA) or circulating tumor cells (CTCs) are key drivers of the EV (extracellular vesicle) based biopsy market. Exosomes are small membrane-bound vesicles released by cells, and they contain various biomolecules, including proteins and nucleic acids. Due to their small size and unique structure, exosomes are present in high numbers in bodily fluids like blood, making them readily accessible for liquid biopsy procedures. In contrast, cfDNA and CTCs might be present in lower quantities, making their isolation and detection more challenging.

Another benefit is that exosomes are stable in bodily fluids. As a result, their cargo does not degrade. This allows for easy transport of the sample and storage of the sample for long periods without loss of bioavailability for the exosome's biomarkers. On the other hand, cfDNA breaks down quickly and CTCs break down in the isolation phase which may affect the sensitivity and accuracy of liquid biopsy tests. The abundance and stability of exosomes provide a significant advantage for liquid biopsies, where access to advanced healthcare facilities might be limited in remote areas. The ease of sample collection and transportation, along with the ability to store samples for extended periods, make exosome-based liquid biopsy a promising diagnostic tool for early detection and monitoring of diseases like cancer.

As the field of liquid biopsy continues to evolve and gain validation, the accessibility and reliability of exosome-based tests are likely to contribute to the growth and adoption of EV-based biopsy technologies in the Paraguayan healthcare system, ultimately leading to improved patient outcomes and personalized medicine approaches.

Rising Prevalence of Cancers

The rising incidence of cancer has significantly impacted the market for EV (extracellular vesicle)-based liquid biopsy. Liquid biopsy is a non-invasive diagnostic method that allows for the detection and monitoring of cancer through the analysis of various biofluids, such as blood or urine, for biomarkers released by tumors. EVs, including exosomes and microvesicles, play a crucial role in this process as they carry valuable information, including DNA, RNA, and proteins, shed by cancer cells into the bloodstream.

One of the primary drivers behind the growing demand for EV-based liquid biopsy is its potential to revolutionize cancer diagnostics and treatment monitoring. Traditional tissue biopsies are invasive, costly, and often provide limited information, while liquid biopsies using EVs offer a less burdensome and more accessible approach. By detecting cancer-specific biomarkers in EVs, clinicians can identify cancer at an early stage, enabling prompt interventions and better treatment outcomes. According to the American Cancer Society, Cancer is the second leading cause of death (after heart disease) in the United States, with an estimated 609,360 people expected to die of cancer in 2022, an average of 1,670 people per day.

In addition, advances in technology and the use of AI-powered data analysis have improved the sensitivity and accuracy of EV liquid biopsy tests. Machine learning algorithms help to identify complex patterns and subtle variations in EV biomarkers. The market's growth is further catalyzed by the increasing investment and research efforts in the field of oncology and liquid biopsy technology. Pharmaceutical companies, diagnostic laboratories, and biotechnology firms are actively collaborating to develop innovative EV-based liquid biopsy products, leading to a competitive market landscape.

Therefore, the rising prevalence of cancer and the urgent need for more efficient and non-invasive diagnostic tools have driven the market for EV-based liquid biopsy. Its potential to provide early cancer detection, real-time monitoring, and personalized treatment options has garnered significant attention from healthcare providers and researchers alike. As technology continues to advance and investments pour into the field, EV-based liquid biopsy is poised to play a pivotal role in revolutionizing cancer diagnosis and patient care.

Growing Investments in Research Development

The increasing investments in research and development (RD) activities related to EV-based liquid biopsy technologies are propelling market growth. Pharmaceutical companies, biotechnology firms, and academic institutions are actively engaged in collaborative research efforts aimed at advancing the understanding of EV biology, developing novel isolation and detection methods, and validating the clinical utility of EV-based biomarkers across various cancer types. These investments drive innovation, foster technological advancements, and expand the repertoire of EV-based liquid biopsy assays available for clinical use. Additionally, strategic partnerships and collaborations between industry players and research organizations accelerate the translation of research findings into commercial products, further stimulating market growth and adoption.

Technological Advancements

Technological advancements play a pivotal role in driving the growth of the Global EV-Based Liquid Biopsy Market. Breakthroughs in areas such as nanotechnology, microfluidics, and sequencing technologies have significantly enhanced the sensitivity, specificity, and throughput of liquid biopsy assays. These advancements enable the detection and characterization of extracellular vesicles (EVs) with unprecedented precision and accuracy, facilitating their utility as minimally invasive biomarkers for cancer detection, monitoring, and treatment response assessment. Furthermore, ongoing research and development efforts focused on refining liquid biopsy platforms and methodologies continue to drive innovation in the field, opening up new opportunities for the commercialization and adoption of EV-based liquid biopsy assays.

Key Market Challenges

Standardization Quality Control

In the Global EV-Based Liquid Biopsy Market, a critical impediment revolves around the absence of standardized protocols and quality control measures. This deficiency poses a significant challenge due to the inherent variability in sample collection, processing, and analysis techniques. Such variability often translates into inconsistent results, thereby compromising the reliability and reproducibility of liquid biopsy tests.

This challenge underscores the pressing need for collaborative efforts among stakeholders to establish uniform procedures and stringent quality assurance protocols. Standardization efforts would encompass every stage of the liquid biopsy workflow, including sample collection, handling, processing, and analysis. By implementing standardized protocols, the industry can mitigate variations introduced by different methodologies and equipment, thereby enhancing the reliability and comparability of liquid biopsy results across laboratories and studies.

Sample Stability and Storage

Ensuring the stability and proper storage of liquid biopsy samples, especially those containing extracellular vesicles (EVs), poses formidable challenges within the Global EV-Based Liquid Biopsy Market. EVs, comprising exosomes and microvesicles, are exquisitely sensitive to environmental conditions and can undergo rapid degradation if not handled and stored meticulously. Maintaining sample stability throughout the collection, processing, and storage stages is paramount to preserving the integrity of EV-based biomarkers and ensuring the accuracy of test results.

Given the inherent fragility of EVs, stringent protocols for sample handling, storage, and transportation are imperative. Standardized procedures must be established to minimize pre-analytical variability and optimize the reproducibility of liquid biopsy assays. These protocols encompass a range of considerations, including the use of appropriate collection tubes and preservatives to prevent EV degradation, ensuring consistent sample processing techniques to minimize artefacts, and implementing robust storage conditions to safeguard sample integrity.

Key Market Trends

Emergence of Novel EV Biomarkers

A significant and notable trend in the Global EV-Based Liquid Biopsy Market revolves around the discovery and validation of novel extracellular vesicle (EV) biomarkers. Comprehension of EV biology progresses, researchers are unraveling a vast array of EV-associated molecules encompassing proteins, nucleic acids, and lipids, each harboring diagnostic and prognostic potential. These novel EV biomarkers represent a paradigm shift in diagnostic approaches, offering distinct advantages over conventional biomarkers such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs).

The inherent versatility of EVs allows them to encapsulate various biomolecules reflective of dynamic cellular processes and microenvironmental changes. As a result, EV-based biomarkers provide a multifaceted glimpse into disease progression, treatment response, and therapeutic resistance. This multifaceted insight holds profound implications for clinical practice, paving the way for early disease detection, precise treatment stratification, and personalized therapeutic interventions.

Expansion of Applications Beyond Oncology

Beyond its prominent role in oncology, the Global EV-Based Liquid Biopsy Market is undergoing a notable expansion into diverse disease areas. Extracellular vesicles (EVs) are increasingly recognized as pivotal mediators of intercellular communication and disease pathogenesis across a spectrum of non-oncological conditions, spanning neurodegenerative diseases, cardiovascular disorders, and infectious diseases. This expanding recognition of EV involvement in disease pathology has sparked a surge of interest in exploring the diagnostic and prognostic potential of EV-based liquid biopsies in these fields.

In the realm of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, EV-based liquid biopsies hold promise for early detection and monitoring of disease progression. EVs encapsulate specific biomolecules reflective of neurodegenerative processes, offering a non-invasive avenue for assessing disease status and response to therapy. By analyzing EV-associated proteins, nucleic acids, and other molecular cargo, researchers aim to develop robust biomarker panels capable of providing insights into disease onset, progression, and treatment efficacy.

Segmental Insights

Offering Insights

Based on the Offering, Kits and Assays emerge as the dominating offering segment. Several factors contribute to the prominence of kits and assays in this market. Kits and assays offer convenience and ease of use for researchers and clinicians, providing standardized protocols and reagents for EV isolation, detection, and characterization. These ready-to-use kits streamline the liquid biopsy workflow, saving time and resources while ensuring consistency and reproducibility of results.

Kits and assays cater to the diverse needs of users across various research and clinical settings, offering a wide range of options for EV isolation methods, biomarker analysis, and downstream applications. Whether researchers are interested in profiling EV-associated proteins, nucleic acids, or lipid molecules, there are kits and assays available to meet their specific requirements.

Workflow Insights

Based on the Workflow segment, the dominant segment concerning workflow is Sample Preparation. This dominance is driven by several key factors. Sample preparation is a critical initial step in the liquid biopsy workflow, involving the isolation and enrichment of extracellular vesicles (EVs) from biological fluids such as blood, urine, and cerebrospinal fluid. Efficient and reliable sample preparation methods are essential for obtaining high-quality EVs for downstream analysis.

Sample preparation methods significantly impact the sensitivity, specificity, and reproducibility of EV-based liquid biopsy assays. As such, there is a strong demand for innovative sample preparation technologies that offer superior EV isolation efficiency, purity, and yield. Commercially available sample preparation kits and systems cater to this demand by providing standardized protocols and reagents optimized for EV isolation from different sample types.

Regional Insights

North America emerges as the dominant region in the Global EV-Based Liquid Biopsy Market. Several factors contribute to North America's dominance in this market segment. North America boasts a robust biomedical research ecosystem, comprising leading academic institutions, research organizations, and biotechnology companies actively engaged in advancing liquid biopsy technologies. The region's strong emphasis on healthcare innovation and investment in research and development foster the development and commercialization of cutting-edge liquid biopsy assays. The presence of well-established regulatory frameworks and clinical infrastructure further accelerates the adoption of EV-based liquid biopsy techniques in clinical practice.

Key Market Players

Horiba Ltd.

Thermo Fisher Scientific, Inc.

Lonza Group AG

Takara Bio Inc.

Abcam plc

Qiagen N.V.

Malvern Panalytical Ltd.

Revvity, Inc. (PerkinElmer, Inc)

Norgen Biotek Corp.

Bio-Techne Corporation

Report Scope:

In this report, the Global EV-Based Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

EV-Based Liquid Biopsy Market, By Offering:

  • Kits and Assays
  • Services
  • Instruments

EV-Based Liquid Biopsy Market, By Workflow:

  • Sample Preparation
  • Sequencing
  • Data Analysis

EV-Based Liquid Biopsy Market, By Technology:

  • Isolation Technologies
  • Analysis Technologies

EV-Based Liquid Biopsy Market, By Sample Type:

  • Blood
  • Urine
  • Saliva
  • Others

EV-Based Liquid Biopsy Market, By End User:

  • Academic and Research Institutes
  • Pharmaceutical and Biotechnology Companies
  • Clinical Laboratories

EV-Based Liquid Biopsy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global EV-Based Liquid Biopsy Market.

Available Customizations:

Global EV-Based Liquid Biopsy marketreport with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, and Trends

4.Clinical Trial Analysis

  • 4.1.Ongoing Clinical Trials
  • 4.2.Completed Clinical Trials
  • 4.3.Terminated Clinical Trials
  • 4.4.Breakdown of Pipeline, By Development Phase
  • 4.5.Breakdown of Pipeline, By Status
  • 4.6.Breakdown of Pipeline, By Therapeutic Area
  • 4.7.Breakdown of Pipeline, By Region
  • 4.8.Clinical Trials Heat Map

5.Voice of Customer

6.Global EV-Based Liquid Biopsy Market Outlook

  • 6.1.Market Size Forecast
    • 6.1.1.By Value
  • 6.2.Market Share Forecast
    • 6.2.1.By Offering (Kits and Assays, Services, Instruments)
    • 6.2.2.By Workflow (Sample Preparation, Sequencing, Data Analysis)
    • 6.2.3.By Technology (Isolation Technologies, Analysis Technologies)
    • 6.2.4.By Sample Type (Blood, Urine, Saliva, and Others)
    • 6.2.5.By End user (Academic and Research Institutes, Pharmaceutical and Biotechnology Companies, Clinical Laboratories)
    • 6.2.6.By Region
    • 6.2.7.By Company (2023)
  • 6.3.Market Map

7.North America EV-Based Liquid Biopsy Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.ByOffering
    • 7.2.2.By Workflow
    • 7.2.3.By Technology
    • 7.2.4.By Sample Type
    • 7.2.5.By End user
    • 7.2.6.By Country
  • 7.3.North America: Country Analysis
    • 7.3.1.United States EV-Based Liquid Biopsy Market Outlook
      • 7.3.1.1.Market Size Forecast
        • 7.3.1.1.1.By Value
      • 7.3.1.2.Market Share Forecast
        • 7.3.1.2.1.By Offering
        • 7.3.1.2.2.By Workflow
        • 7.3.1.2.3.By Technology
        • 7.3.1.2.4.By Sample Type
        • 7.3.1.2.5.By End user
    • 7.3.2.Canada EV-Based Liquid Biopsy Market Outlook
      • 7.3.2.1.Market Size Forecast
        • 7.3.2.1.1.By Value
      • 7.3.2.2.Market Share Forecast
        • 7.3.2.2.1.By Offering
        • 7.3.2.2.2.By Workflow
        • 7.3.2.2.3.By Technology
        • 7.3.2.2.4.By Sample Type
        • 7.3.2.2.5.By End user
    • 7.3.3.Mexico EV-Based Liquid Biopsy Market Outlook
      • 7.3.3.1.Market Size Forecast
        • 7.3.3.1.1.By Value
      • 7.3.3.2.Market Share Forecast
        • 7.3.3.2.1.By Offering
        • 7.3.3.2.2.By Workflow
        • 7.3.3.2.3.By Technology
        • 7.3.3.2.4.By Sample Type
        • 7.3.3.2.5.By End user

8.Europe EV-Based Liquid Biopsy Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Offering
    • 8.2.2.By Workflow
    • 8.2.3.By Technology
    • 8.2.4.By Sample Type
    • 8.2.5.By End user
    • 8.2.6.By Country
  • 8.3.Europe: Country Analysis
    • 8.3.1.Germany EV-Based Liquid Biopsy Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Offering
        • 8.3.1.2.2.By Workflow
        • 8.3.1.2.3.By Technology
        • 8.3.1.2.4.By Sample Type
        • 8.3.1.2.5.By End user
    • 8.3.2.Italy EV-Based Liquid Biopsy Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Offering
        • 8.3.2.2.2.By Workflow
        • 8.3.2.2.3.By Technology
        • 8.3.2.2.4.By Sample Type
        • 8.3.2.2.5.By End user
    • 8.3.3.France EV-Based Liquid Biopsy Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Offering
        • 8.3.3.2.2.By Workflow
        • 8.3.3.2.3.By Technology
        • 8.3.3.2.4.By Sample Type
        • 8.3.3.2.5.By End user
    • 8.3.4.Spain EV-Based Liquid Biopsy Market Outlook
      • 8.3.4.1.Market Size Forecast
        • 8.3.4.1.1.By Value
      • 8.3.4.2.Market Share Forecast
        • 8.3.4.2.1.By Offering
        • 8.3.4.2.2.By Workflow
        • 8.3.4.2.3.By Technology
        • 8.3.4.2.4.By Sample Type
        • 8.3.4.2.5.By End user
    • 8.3.5.United Kingdom EV-Based Liquid Biopsy Market Outlook
      • 8.3.5.1.Market Size Forecast
        • 8.3.5.1.1.By Value
      • 8.3.5.2.Market Share Forecast
        • 8.3.5.2.1.By Offering
        • 8.3.5.2.2.By Workflow
        • 8.3.5.2.3.By Technology
        • 8.3.5.2.4.By Sample Type
        • 8.3.5.2.5.By End user

9.Asia-Pacific EV-Based Liquid Biopsy Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Offering
    • 9.2.2.By Workflow
    • 9.2.3.By Technology
    • 9.2.4.By Sample Type
    • 9.2.5.By End user
    • 9.2.6.By Country
  • 9.3.Asia Pacific: Country Analysis
    • 9.3.1.China EV-Based Liquid Biopsy Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Offering
        • 9.3.1.2.2.By Workflow
        • 9.3.1.2.3.By Technology
        • 9.3.1.2.4.By Sample Type
        • 9.3.1.2.5.By End user
    • 9.3.2.Japan EV-Based Liquid Biopsy Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Offering
        • 9.3.2.2.2.By Workflow
        • 9.3.2.2.3.By Technology
        • 9.3.2.2.4.By Sample Type
        • 9.3.2.2.5.By End user
    • 9.3.3.India EV-Based Liquid Biopsy Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Offering
        • 9.3.3.2.2.By Workflow
        • 9.3.3.2.3.By Technology
        • 9.3.3.2.4.By Sample Type
        • 9.3.3.2.5.By End user
    • 9.3.4.Australia EV-Based Liquid Biopsy Market Outlook
      • 9.3.4.1.Market Size Forecast
        • 9.3.4.1.1.By Value
      • 9.3.4.2.Market Share Forecast
        • 9.3.4.2.1.By Offering
        • 9.3.4.2.2.By Workflow
        • 9.3.4.2.3.By Technology
        • 9.3.4.2.4.By Sample Type
        • 9.3.4.2.5.By End user
    • 9.3.5.South Korea EV-Based Liquid Biopsy Market Outlook
      • 9.3.5.1.Market Size Forecast
        • 9.3.5.1.1.By Value
      • 9.3.5.2.Market Share Forecast
        • 9.3.5.2.1.By Offering
        • 9.3.5.2.2.By Workflow
        • 9.3.5.2.3.By Technology
        • 9.3.5.2.4.By Sample Type
        • 9.3.5.2.5.By End user

10.Middle East and Africa EV-Based Liquid Biopsy Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Offering
    • 10.2.2.By Workflow
    • 10.2.3.By Technology
    • 10.2.4.By Sample Type
    • 10.2.5.By End user
    • 10.2.6.By Country
  • 10.3.Middle East and Africa: Country Analysis
    • 10.3.1.UAE EV-Based Liquid Biopsy Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.By Offering
        • 10.3.1.2.2.By Workflow
        • 10.3.1.2.3.By Technology
        • 10.3.1.2.4.By Sample Type
        • 10.3.1.2.5.By End user
    • 10.3.2.Saudi Arabia EV-Based Liquid Biopsy Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.By Offering
        • 10.3.2.2.2.By Workflow
        • 10.3.2.2.3.By Technology
        • 10.3.2.2.4.By Sample Type
        • 10.3.2.2.5.By End user
    • 10.3.3.South Africa EV-Based Liquid Biopsy Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.By Offering
        • 10.3.3.2.2.By Workflow
        • 10.3.3.2.3.By Technology
        • 10.3.3.2.4.By Sample Type
        • 10.3.3.2.5.By End user

11.South America EV-Based Liquid Biopsy Market Outlook

  • 11.1.Market Size Forecast
    • 11.1.1.By Value
  • 11.2.Market Share Forecast
    • 11.2.1.By Offering
    • 11.2.2.By Workflow
    • 11.2.3.By Technology
    • 11.2.4.By Sample Type
    • 11.2.5.By End user
    • 11.2.6.By Country
  • 11.3.South America: Country Analysis
    • 11.3.1.Brazil EV-Based Liquid Biopsy Market Outlook
      • 11.3.1.1.Market Size Forecast
        • 11.3.1.1.1.By Value
      • 11.3.1.2.Market Share Forecast
        • 11.3.1.2.1.By Offering
        • 11.3.1.2.2.By Workflow
        • 11.3.1.2.3.By Technology
        • 11.3.1.2.4.By Sample Type
        • 11.3.1.2.5.By End user
    • 11.3.2.Argentina EV-Based Liquid Biopsy Market Outlook
      • 11.3.2.1.Market Size Forecast
        • 11.3.2.1.1.By Value
      • 11.3.2.2.Market Share Forecast
        • 11.3.2.2.1.By Offering
        • 11.3.2.2.2.By Workflow
        • 11.3.2.2.3.By Technology
        • 11.3.2.2.4.By Sample Type
        • 11.3.2.2.5.By End user
    • 11.3.3.Colombia EV-Based Liquid Biopsy Market Outlook
      • 11.3.3.1.Market Size Forecast
        • 11.3.3.1.1.By Value
      • 11.3.3.2.Market Share Forecast
        • 11.3.3.2.1.By Offering
        • 11.3.3.2.2.By Workflow
        • 11.3.3.2.3.By Technology
        • 11.3.3.2.4.By Sample Type
        • 11.3.3.2.5.By End user

12.Market Dynamics

  • 12.1.Drivers
  • 12.2.Challenges

13.Market Trends Developments

  • 13.1.Merger Acquisition (If Any)
  • 13.2.Product Launches (If Any)
  • 13.3.Recent Developments

14.Porters Five Forces Analysis

  • 14.1.Competition in the Industry
  • 14.2.Potential of New Entrants
  • 14.3.Power of Suppliers
  • 14.4.Power of Customers
  • 14.5.Threat of Substitute Products

15.Competitive Landscape

  • 15.1.Horiba Ltd.
    • 15.1.1.Business Overview
    • 15.1.2.Company Snapshot
    • 15.1.3.Products Services
    • 15.1.4.Financials (As Reported)
    • 15.1.5.Recent Developments
    • 15.1.6.Key Personnel Details
    • 15.1.7.SWOT Analysis
  • 15.2.Thermo Fisher Scientific, Inc
  • 15.3.Lonza Group AG
  • 15.4.Takara Bio Inc
  • 15.5.Abcam plc
  • 15.6.Qiagen N.V
  • 15.7.Malvern Panalytical Ltd
  • 15.8.Revvity, Inc. (PerkinElmer, Inc)
  • 15.9.Norgen Biotek Corp
  • 15.10.Bio-Techne Corporation

16.Strategic Recommendations

17.About Us Disclaimer